Displaying 1 - 20 of 881
Download
PIPS Search Results
PIP Number Active Substance Conditions / Indications Invented Name Therapeutic area Decision Type Compliance Check Compliance outcome Date Published
MHRA-100709-PIP01-22-M02 (update)
  • Rozanolixizumab
  • Treatment of myasthenia gravis
  • Neurology
 PM: decision on the application for modification of an agreed paediatric investigation plan. No
MHRA-100369-PIP01-21-M02 (update)
  • MIGALASTAT HYDROCHLORIDE
  • Treatment of Fabry disease
  • Galafold 123 mg capsules
  • Galafold
  • Galafold
  • Endocrinology-Gynaecology-Fertility-metabolism
 PM: decision on the application for modification of an agreed paediatric investigation plan. No
MHRA-101857-PIP01-25
  • Humanised afucosylated IgG1 monoclonal antibody against CCR8
  • Treatment of all conditions included in the category of malignant neoplasms except melanoma, nervous system neoplasms, haematopoietic and lymphoid tissue neoplasms
  • Oncology
 W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101641-PIP01-24
  • Japanese encephalitis virus, strain SA14-14-2, Live
  • Prevention of Japanese encephalitis
  • IMOJEV
  • IMOJEV
  • IMOJEV
  • Infectious diseases
  • Vaccines
 P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s) No
MHRA-101404-PIP01-24-M01 (update)
  • TRASTUZUMAB DERUXTECAN
  • Treatment of all conditions in the category of malignant neoplasms (except haematopoietic and lymphoid tissue neoplasms)
  • Enhertu
  • Enhertu
  • Oncology
 PM: decision on the application for modification of an agreed paediatric investigation plan. No
MHRA-101356-PIP01-24-M01 (update)
  • inebilizumab
  • Treatment of myasthenia gravis
  • Uplizna
  • Uplizna
  • Uplizna
  • Uplizna
  • Uplizna
  • Xinyue
  • Uplizna
  • Uplizna
  • Uplizna
  • Uplizna
  • Uplizna
  • Uplizna
  • Neurology
 PM: decision on the application for modification of an agreed paediatric investigation plan. No
MHRA-100230-PIP01-21-M01 (update)
  • Nerandomilast
  • Treatment of fibrosing interstitial lung disease
  • Pneumology - Allergology
 PM: decision on the application for modification of an agreed paediatric investigation plan. No
MHRA-100439-PIP01-22-M01 (update)
  • Asundexian
  • Prevention of arterial thromboembolism
  • Not available at present
  • Cardiovascular Diseases
 PM: decision on the application for modification of an agreed paediatric investigation plan. No
MHRA-100253-PIP01-21-M02 (update)
  • Zuranolone
  • Treatment of postpartum depression
  • Zurzuvae
  • Psychiatry
 PM: decision on the application for modification of an agreed paediatric investigation plan. No
MHRA-100145-PIP01-21-M02 (update)
  • BRIGATINIB
  • Treatment of non-small cell lung cancer (NSCLC)
  • Treatment of anaplastic large cell lymphoma (ALCL)
  • Treatment of Inflammatory myofibroblastic tumours
  • Oncology
 PM: decision on the application for modification of an agreed paediatric investigation plan. No
MHRA-100578-PIP01-22-M01 (update)
  • SEMAGLUTIDE
  • Cagrilintide
  • Treatment of obesity
  • Endocrinology-Gynaecology-Fertility-metabolism
 PM: decision on the application for modification of an agreed paediatric investigation plan. No
MHRA-101908-PIP01-25-M01 (update)
  • MOSUNETUZUMAB
  • Treatment of mature B-cell neoplasms
  • Lunsumio
  • Haematology-Hemostaseology
 PM: decision on the application for modification of an agreed paediatric investigation plan. No
MHRA-101447-PIP01-24-M02 (update)
  • DIFELIKEFALIN ACETATE
  • Treatment of chronic kidney disease associated pruritus.
  • Kapruvia
  • Kapruvia
  • Other: Nephrology
 PM: decision on the application for modification of an agreed paediatric investigation plan. No
MHRA-100443-PIP01-22-M05 (update)
  • BARICITINIB
  • Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, ankylosing spondylarthritis, psoriatic arthritis and juvenile idiopathic arthritis)
  • Olumiant
  • Immunology -Rheumatology-Transplantation
 PM: decision on the application for modification of an agreed paediatric investigation plan. Yes
MHRA-100349-PIP01-21-M03 (update)
  • Rezafungin acetate
  • Treatment of invasive candidiasis
  • Rezzayo
  • Rezzayo
  • Infectious diseases
 PM: decision on the application for modification of an agreed paediatric investigation plan. No
MHRA-101916-PIP01-25
  • PF-07248144
  • Treatment of breast cancer
  • Oncology
 W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-101909-PIP01-25
  • 5,8-dichloro-2-[(4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl]-7-[(R)-methoxy(oxetan-3-yl)methyl]-3,4-dihydroisoquinolin-1(2H)-one
  • Treatment of prostate malignant neoplasms
  • Oncology
 W: decision granting a waiver in all age groups for the listed condition(s). No
MHRA-100462-PIP01-22-M03 (update)
  • FENFLURAMINE HYDROCHLORIDE
  • Treatment of Dravet syndrome.
  • Fintepla
  • Fintepla
  • Fintepla
  • Fintepla
  • Fintepla
  • Neurology
 PM: decision on the application for modification of an agreed paediatric investigation plan. No
MHRA-101879-PIP01-25-M01 (update)
  • BECLOMETASONE DIPROPIONATE
  • FORMOTEROL FUMARATE DIHYDRATE
  • GLYCOPYRRONIUM BROMIDE
  • Treatment of asthma
  • Trimbow
  • Trimbow
  • Trimbow
  • Trimbow
  • Trimbow
  • Trimbow
  • Trimbow
  • Trimbow
  • Trimbow
  • Trimbow
  • Trimbow
  • Trimbow
  • Trimbow
  • Trimbow
  • Trimbow
  • Trimbow
  • Trimbow
  • Trimbow
  • Trimbow
  • Trimbow
  • Trimbow
  • Trimbow
  • Trimbow
  • Trimbow
  • Trimbow
  • Trimbow
  • Trimbow
  • Trimbow
  • Pneumology - Allergology
 PM: decision on the application for modification of an agreed paediatric investigation plan. Yes
MHRA-101159-PIP02-25
  • Sacituzumab Tirumotecan
  • Treatment of urothelial carcinoma
  • sac-TMT (佳泰莱®)
  • Oncology
 W: decision granting a waiver in all age groups for the listed condition(s). No
Download XLSX